Novel connecting tube for saline chaser in contrast-enhanced CT: the effect of spiral flow of saline on contrast enhancement

Simultaneous Injection of Contrast and Saline Using Spiral Flow-Generating Tube for Hepatic Dynamic Computed Tomography: Effect on Enhancement of Liver Parenchyma and Metastases to the Liver

PURPOSE

Recently, there have been a few reports regarding the usefulness of a novel saline injection technique using a spiral flow-generating tube. The purpose of this study was to evaluate whether simultaneous saline injection using a spiral flow-generating tube was able to improve hepatic contrast enhancement and lesion conspicuity of metastatic liver tumors.

METHODS

We randomized a total of 411 patients with various liver diseases including metastases by total body weight (A, n = 204) and contrast dilution protocol (B, n = 207). Group A received 400 mgI/kg of contrast medium alone without a spiral flow-generating tube; group B received contrast medium 400 mgI/kg simultaneous with injection of a 0.57-ml/kg physiologic saline solution through a spiral flow-generating tube. Abdominal aorta computed tomography (CT) number, hepatic enhancement (ΔHU), percentage of tests demonstrating an enhancement effect of the liver parenchyma exceeding Δ50 HU in 3 measured segments (S2, S6, and S8), and the contrast-to-noise ratio of the metastatic liver tumors were measured.

RESULTS

The mean aortic CT number of group B (417.0 HU ± 61.7; P < 0.01) was approximately 10% higher than that of group A (384.6 ± 79.1 HU). The average ΔHU was 59.8 ± 11.4 HU for group A and 61.7 ± 11.7 for group B. The ΔHU for group B was significantly higher than that for group A ( P = 0.017). The percentage of tests demonstrating with the enhancement effect of group B was more than 80% in all subgroups; however, that of group A was less than 80% in all subgroups. The contrast-to-noise ratio of group B (7.8 ± 3.3 HU) was significantly higher compared to that of group A (6.5 ± 2.8 HU) ( P < 0.05).

CONCLUSIONS

Because of the volume effect, injecting a contrast medium diluted with normal saline improved the degree of hepatic and aortic contrast enhancement and achieved better visualization of liver metastases.

CLINICAL IMPACT

The use of spiral flow-generating tube may help diagnostic of hepatic and aortic contrast enhancement and liver metastases.

IMPORTANCE

The use of a spiral flow-generating tube improved the degree of hepatic and aortic contrast enhancement and achieve better visualization of liver metastases.

POINTS

The use of low-concentration syringe formulations is limited by body weight. However, the use of spiral flow-generating tube provides low-concentration contrast medium regardless of body weight.

Improvement in arterial enhancement using diluted injection of contrast medium in CT angiography

BACKGROUND

Arterial enhancement after contrast injection affects the quality of computed tomography angiography (CTA) images.

PURPOSE

To evaluate whether the dilution of contrast medium (CM) for CTA increases arterial enhancement after the adjustment of iodine concentration as per the patient's body weight (BW).

MATERIAL AND METHODS

We retrospectively studied 700 patients who underwent coronary CTA. The first 350 consecutive patients underwent standard CTA with a fixed iodine concentration, whereas the remaining 350 underwent CTA with a diluted CM injection. All patients were classified into three groups according to their BW (<55, 55-65, and 66-73 kg). The mean and proportion of contrast enhancements (CEs) in the ascending aorta of ≥350 Hounsfield units (HUs) (CE₃₅₀) were compared between the standard CTA and diluted CM injection and among the BW groups. The associations between BW and CE were analyzed using linear regression.

RESULTS

Receiving diluted CM increased the mean CE in the <55-kg group (403.4 ± 55.4 HU vs. 382.8 ± 59.3 HU; P < 0.01) but not in the groups with heavier BW. The proportion of patients with CE₃₅₀ increased with BW (<55 kg = 71%, 55-65 kg = 84%, and 66-73 kg = 91%) and increased after dilution (86%, 93%, and 96%, respectively). After CM dilution, the correlation between BW and CE among patients undergoing CTA decreased from 0.37 to 0.22 (P < 0.05).

CONCLUSION

CM dilution for CTA improves arterial enhancement.

Proposal of a novel protocol using estimated cardiac index fractional dose to improve aortic contrast enhancement for early-phase dynamic CT

Maximum aortic computed tomography value (CTV) is difficult to control because of variations in cardiac function and patient physique. Therefore, to improve early-phase aortic enhancement on dynamic computed tomography (CT), we developed an estimated cardiac index fractional dose (eciFD). The eciFD protocol is a novel and original protocol for administering fractional dose (FD), representing the amount of iodine per unit body weight per injection duration, based on cardiac index (cardiac output divided by body surface area) as estimated by age in early-phase dynamic CT. At the time of administration, by selecting FD based on the patient's age and selecting a parameter that can achieve this FD, an aortic CTV ≥300 HU (ACTV≥300) can be obtained. This study aimed to investigate aortic enhancement on CT angiography using the eciFD protocol.This retrospective study investigated 291 consecutive patients who underwent dynamic CT from neck to abdomen after recommendation of the eciFD protocol at our institution. We compared early-phase aortic CTV distributions by scan delay between an eciFD group (eciFD applied, n = 135) and a non-eciFD group (eciFD not applied, n = 80). The effect of eciFD on early-phase ACTV≥300 was evaluated using logistic regression analysis adjusted for several potentially meaningful clinical confounders related to aortic CTV, namely male sex, heart rate ≤80 beats/min, estimated glomerular filtration rate ≤40 mL/min, use of eciFD, bolus tracking (BT), history of myocardial infarction, and order from the emergency center.The eciFD protocol was a significant factor for early-phase ACTV≥300 after adjusting for several confounders (odds ratio 3.03; 95% confidence intervals 1.59-5.77; P = .001). No interaction was seen between BT and eciFD protocol (p for interaction = 0.76). In terms of CTV distribution, with both a fixed scan delay time and BT, the eciFD group showed a high aortic CTV. The combination of eciFD protocol with BT provided a particularly high percentage of patients with ACTV≥300 (86.4%).The eciFD protocol was useful for improving aortic contrast enhancement. These findings need to be validated in a randomized controlled study.

Efficacy of the spiral flow generating extended tube during paediatric CCTA

INTRODUCTION

To compare the computed tomography (CT) number for paediatric cardiac computed tomography angiography (CCTA) and visualisation score of the three-dimensional (3D) images using the conventional T-shaped extended tube (T-tube) and spiral flow-generating extended tube (spiral-tube) connected between the contrast injector and cannula.

METHODS

In total, 108 patients suspected to have congenital heart disease (CHD) were considered for inclusion. We utilised the T-tube for intravenous contrast and spiral-tube in 54 patients each. Observers individually inspected randomized volume rendering images of the internal thoracic artery, each acquired from the with or without spiral-tube groups, using a four-point scale. We compared the mean CT number of the ascending aorta (AAO) and pulmonary artery (PA), contrast noise ratio (CNR), CT number for the AAO and PA enhancement ratio, and the visualisation scores between the groups.

RESULTS

There were no significant differences in patient characteristics between the with or without spiral-tube groups (p > 0.05). The mean CT number ±standard deviation for the AAO and PA, and the CNR without or with spiral-tube groups were 441.2 ± 89.2 and 489.8 ± 86.1 HU for the AAO, 436.3 ± 100.6 and 475.3 ± 85.2 HU for the PA, and 9.5 ± 2.2 and 10.8 ± 2.4 for the CNR, respectively (p < 0.05). In the spiral-tube group, the CT number, CNR, and visualisations score of the 3D images were significantly higher for the AAO and PA than those in the T-tube group (p < 0.05).

CONCLUSION

The spiral-tube proved to be beneficial in improving the CT number for the AAO and PA, CNR, and visualisation score compared with the conventional T-tube during paediatric CCTA.

IMPLICATIONS FOR PRACTICE

The spiral-tube may allow the visualisation of smaller blood vessels than those visualised by the conventional T-tube for paediatric patients in CCTA.

In Vitro Investigation of an Electrically Actuated Antireflux Valve for a Multiuse Contrast Agent Injection System

OBJECTIVE. The purpose of this study was to determine the capability of a newly developed antireflux valve for a multiuse contrast agent injection system. MATERIALS AND METHODS. Multiuse contrast agent injection systems require an antireflux valve to eliminate the risk of cross-patient blood contamination. An electrically actuated antireflux valve developed for this purpose can control risk of contamination because it is under forced control and surveillance. In this study, the injection system was connected to a pulsatile circulation system that reproduced an aortic flow environment in vitro. The transvalvular pressure difference was measured, and flow dynamics during valve opening and closing were visualized by high-speed flow visualization. A total of 30 injection conditions were tested, which included two catheters (6- and 2-French diameter), five contrast agent concentrations (100%, 90%, 50%, 10%, and 0%), and a wide range of flow rates (0.1-25.0 mL/s). RESULTS. The transvalvular pressure difference and flow dynamics during valve opening and closing were characterized. Just before valve opening, a minimum transvalvular pressure difference of 0.20 MPa (1500 mm Hg) was confirmed. The positive pressure difference prevented regurgitation during valve opening. During valve closing, the front of the backflow was monitored continuously, and we confirmed that the front failed to reach the valve before complete closure. CONCLUSION. This study provided proof of concept for an electrically actuated antireflux valve to be used in a multiuse contrast agent injection system.

Technique, protocols and adverse reactions for contrast-enhanced spectral mammography (CESM): a systematic review

We reviewed technical parameters, acquisition protocols and adverse reactions (ARs) for contrast-enhanced spectral mammography (CESM). A systematic search in databases, including MEDLINE/EMBASE, was performed to extract publication year, country of origin, study design; patients; mammography unit/vendor, radiation dose, low-/high-energy tube voltage; contrast molecule, concentration and dose; injection modality, ARs and acquisition delay; order of views; examination time. Of 120 retrieved articles, 84 were included from 22 countries (September 2003-January 2019), totalling 14012 patients. Design was prospective in 44/84 studies (52%); in 70/84 articles (83%), a General Electric unit with factory-set kVp was used. Per-view average glandular dose, reported in 12/84 studies (14%), ranged 0.43-2.65 mGy. Contrast type/concentration was reported in 79/84 studies (94%), with Iohexol 350 mgI/mL mostly used (25/79, 32%), dose and flow rate in 72/84 (86%), with 1.5 mL/kg dose at 3 mL/s in 62/72 studies (86%). Injection was described in 69/84 articles (82%), automated in 59/69 (85%), manual in 10/69 (15%) and flush in 35/84 (42%), with 10-30 mL dose in 19/35 (54%). An examination time < 10 min was reported in 65/84 studies (77%), 120 s acquisition delay in 65/84 (77%) and order of views in 42/84 (50%) studies, beginning with the craniocaudal view of the non-suspected breast in 7/42 (17%). Thirty ARs were reported by 14/84 (17%) studies (26 mild, 3 moderate, 1 severe non-fatal) with a pooled rate of 0.82% (fixed-effect model). Only half of CESM studies were prospective; factory-set kVp, contrast 1.5 mL/kg at 3 mL/s and 120 s acquisition delay were mostly used; only 1 severe AR was reported. CESM protocol standardisation is advisable.

Verification of the Dose Reduction Effect via Diluted Injection in Dual-Energy Computed Tomography Using a Human Blood Flow Phantom

Purpose. We sought to examine the possibility of reducing the contrast medium dosage in dual-energy imaging using a saline-mixed injection with a virtual monochromatic energy method of dual-source computed tomography (CT). Methods. An X-ray CT (SOMATOM Definition Flash: Siemens, Nurnberg, Germany) was employed. The mixing ratio of contrast medium and saline was gradually changed by 10%, followed by a mixed injection into a dynamic blood flow phantom (Nemoto Kyorindo, Japan) which is a hemodynamic simulation phantom to obtain time-enhancement curves (TECs). Exactly 64 TECs were prepared for each mixing ratio by changing the energy from 40 to 75 keV for monoenergetic imaging. The relationship between the image standard deviation (SD) and the energy of the virtual monochromatic image was determined. Combinations of the mixing ratio and energy (keV), which can maintain high CT numbers and low image SDs for 3D imaging, were tested, and the reduction rate of the contrast medium was calculated. Results. The TECs for the mixed injection method changed linearly with the dilution rates. The mixing ratios were strongly correlated with the maximum CT number of the TEC (R2 = 0.98). Contrast CT numbers and image SDs increased by approximately 20% and 25%, respectively, as the energy decreased by 5 keV. The optimal conditions for reducing the contrast medium dose were a mixing ratio of 6:4 and 55 keV of energy. Conclusion. The virtual monochromatic energy method reduced the contrast medium dosage by up to 40% for three-dimensional CT-angio (3DCTA) tests.

Double ROI Timing Bolus Technique to Perform Aortic CT Angiography With a 9-Second Contrast Injection Duration

OBJECTIVE. The purpose of this study was to investigate the feasibility of a double ROI timing bolus technique for performing aortic CT angiography (CTA) with 40 mL of contrast medium over 9 seconds. SUBJECTS AND METHODS. A prospective study from February to July 2018 included 106 patients with clinical indications for evaluation of aortic aneurysm or dissection or suspected aortic disease. Forty-seven of these patients had undergone prior aortic CTA by the conventional method. The scanning speed for the double ROI timing bolus technique was calculated from the time-attenuation curves of the ascending and descending aorta by use of the timing bolus data to synchronize aortic flow. The conventional scan was obtained by injection of 1.7 mL of contrast medium per kilogram of body weight for 25 seconds. Enhancement of six points on the aortoiliac arteries and superior vena cava was measured. The t test was used to compare the values. RESULTS. Use of the double ROI timing bolus method significantly reduced the amount of contrast medium injected compared with the amount for the conventional method (40.0 mL vs 88.0 ± 9.4 mL, p < 0.001). Use of the method significantly increased aortoiliac enhancement (403.3 ± 76.0 HU vs 359.7 ± 61.5 HU, p < 0.001) and significantly decreased enhancement of the superior vena cava (118.9 ± 46.2 HU vs 239.2 ± 130.5 HU, p < 0.001) compared with the conventional method. In the group with prior CTA images available, the effective dose was significantly lower with the double ROI timing bolus than with the conventional method (8.3 ± 1.7 mSv vs 12.4 ± 3.2 mSv, p < 0.01). CONCLUSION. Use of the double ROI timing bolus method can dramatically reduce the amount of contrast medium used during aortic CTA while improving aortic enhancement and reducing radiation dose.

Spiral flow-generating tube for saline chaser improves aortic enhancement in Gd-EOB-DTPA-enhanced hepatic MRI

OBJECTIVES

To evaluate the effect of a spiral tube on contrast enhancement in the hepatic arterial phase (HAP) of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI).

METHODS

In this retrospective study, we observed 104 patients who underwent dynamic MRI of the liver between October 2017 and December 2017. Three Gd-EOB-DTPA injection protocols were compared: (A) conventional method (undiluted Gd-EOB-DTPA, injection rate 1 ml/s, n = 36); (B) spiral dilution method (1:1 diluted Gd-EOB-DTPA with saline [off-label], injection rate 2 ml/s via spiral tube, n = 38); (C) spiral-flushed method (undiluted Gd-EOB-DTPA, injection rate 1 ml/s via spiral tube, n = 30). We regarded protocol-A as a control. The signal-to-noise ratio (SNR) of the abdominal aorta was calculated using arterial phase images. Image contrast and artefacts were evaluated by two board-certified radiologists, using a four-point scale. Statistical analyses included Dunnett's test, the Kruskal-Wallis test and the Steel test.

RESULTS

The SNR of the aorta was significantly higher with protocol-C (25.4 ± 8.8) than protocol-A (20.8 ± 5.4, p = 0.01). There was no significant difference in SNR between protocols A and B (p = 0.47). The contrast score of protocol-C was significantly higher than that of protocol-A (p = 0.0019). There was no significant difference in contrast score between protocols A and B (p = 0.50). There was no significant difference in artefacts among the three protocols (p = 0.96).

CONCLUSIONS

Use of a spiral tube with a slow injection protocol contributed to improved aortic contrast enhancement in the HAP of GD-EOB-DTPA-enhanced hepatic MRI.

KEY POINTS

• Gadoxetic acid shows weaker arterial enhancement at recommended doses, compared with nonspecific gadolinium agents; selection of an appropriate injection protocol is important. • A spiral flow-generating tube improves the transport efficiency of the contrast media, and increases the signal-to-noise ratio of the aorta in hepatic arterial phase. • A spiral flow-generating tube does not contribute to artefact reduction in hepatic arterial phase.